The mythology of hormone replacement therapy

Beda Hartmann, B W Hartmann, J C Huber, Johannes C. Huber
British journal of obstetrics and gynaecology · 1997 · vol. 104(2) , pp. 163–168 · doi:10.1111/j.1471-0528.1997.tb11038.x · PMID:9070132 · W2012668491
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

OBJECTIVE: To evaluate the literature on contraindications contained in pharmaceutical data sheets of five currently available oestrogen replacement preparations (HRT). These contraindications include cardiovascular disease, diabetes, liver diseases, otosclerosis, endometriosis, melanoma and hormone-dependent tumours. DESIGN: Systematic review. INTERVENTIONS: Oestrogen replacement regimens. RESULTS: The contraindications to the five HRT preparations have been taken uncritically from the data sheets of oral contraceptives. In some of these conditions not only is HRT not contraindicated, it is indicated. The data sheets for the HRT preparations all state that cardiovascular disease is a contraindication, but systematic review shows that ischaemic heart disease, hypertension and hyperlipidaemia are not contraindications, and in ischaemic heart disease HRT may actually be indicated. Similarly, systematic review shows that diabetes, chronic liver disease, endometriosis, some cases of treated cancer of the endometrium and breast, melanoma and otosclerosis are not contraindications to HRT. CONCLUSIONS: The information in the pharmaceutical data sheets of HRT regimens should be modified as more accurate information could influence how these preparations are prescribed by doctors as well as affect patient compliance.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Estrogen Replacement Therapy Breast Neoplasms Breast Neoplasms Cardiovascular Diseases Cardiovascular Diseases Contraindications Diabetes Complications Endometriosis Endometriosis Female Humans Liver Diseases Liver Diseases Melanoma Melanoma Neoplasms, Hormone-Dependent Neoplasms, Hormone-Dependent Otosclerosis Otosclerosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:52.568893+00:00
License: CC0 · commercial use OK